AI Summary Vemlidy (tenofovir alafenamide) is a nucleotide reverse transcriptase inhibitor and a preferred first-line oral antiviral for chronic hepatitis B, typically dosed at 25 mg once daily.
Medically reviewed.
Vemlidy (tenofovir alafenamide) is a prescription antiviral medication used to treat chronic hepatitis B virus (HBV) infection in adults and certain pediatric patients. It belongs to a class of drugs called nucleotide reverse transcriptase inhibitors (NRTIs) and is a newer formulation of tenofovir designed to deliver the drug more efficiently to liver cells while reducing systemic exposure. Treatment decisions should always be individualized and guided by a healthcare professional.
This page covers Vemlidy's role in chronic hepatitis B management — how it works, who may be eligible, benefits, side effects, and monitoring. You can also connect with a liver specialist near you for personalized guidance on whether Vemlidy fits your care plan.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
ABOUT VEMLIDY TREATMENT
Vemlidy is a prescription medicine whose active ingredient is tenofovir alafenamide (TAF). It belongs to a class of medications called nucleotide reverse transcriptase inhibitors (NRTIs). Vemlidy is used to treat chronic hepatitis B virus (HBV) infection in adults and certain pediatric patients.
Vemlidy is a newer formulation of tenofovir designed to deliver the drug more efficiently into liver cells while reducing the amount of drug that circulates elsewhere in the body. This targeted delivery gives Vemlidy an improved kidney and bone safety profile compared with the older tenofovir formulation, tenofovir disoproxil fumarate (Viread).
Vemlidy is one of the preferred first-line oral therapies for chronic hepatitis B, alongside entecavir (Baraclude) and Viread. It is typically used long-term, alongside regular monitoring by your healthcare provider, such as Liver Function Tests (LFTs) and HBV viral load testing, to track viral suppression and treatment safety.
WHO VEMLIDY MAY BE SUITABLE FOR
Eligibility for Vemlidy depends on your diagnosis, disease activity, and individual health needs. Vemlidy is approved for adults and certain pediatric patients with chronic hepatitis B who need long-term antiviral therapy — for example, those with a durable need for viral suppression, evidence of liver disease progression, or a preference for a treatment option with an improved kidney and bone safety profile.
Clinical guidelines generally recommend starting antiviral treatment for chronic hepatitis B when HBV DNA levels are above 2,000 IU/mL, ALT is above the upper limit of normal, and there is at least moderate liver inflammation or fibrosis on biopsy or non-invasive testing. People with HBV DNA above 20,000 IU/mL and ALT more than twice the upper limit of normal are generally treated regardless of fibrosis stage. Tenofovir alafenamide is one of three nucleos(t)ide analogues generally preferred for first-line treatment, along with entecavir and tenofovir disoproxil fumarate.
Because every patient's health profile is different, there is no one-size-fits-all answer to who should take Vemlidy. Treatment decisions are individualized and should be made by a qualified healthcare professional after a full assessment of your liver condition, viral load, and treatment goals.
ELIGIBILITY OVERVIEW
Vemlidy may be considered for adults and certain pediatric patients with the following conditions, risk factors, or treatment goals:
Before recommending Vemlidy, healthcare providers evaluate several factors to determine whether it is an appropriate option, including:
HOW VEMLIDY CAN HELP YOUR LIVER
Vemlidy inhibits hepatitis B viral DNA replication inside liver cells. Because it is designed to deliver tenofovir more efficiently to hepatocytes (liver cells) while lowering systemic exposure, it targets the virus where it replicates while reducing the amount of drug circulating elsewhere in the body.
As viral replication slows, the amount of HBV DNA in the bloodstream (viral load) falls, and liver inflammation tends to ease. Over time, this can help slow the progression of fibrosis and cirrhosis linked to chronic hepatitis B.
For patients with chronic hepatitis B, these effects support treatment goals such as durable viral suppression, reduced liver inflammation, and a lower risk of disease progression. Vemlidy is generally used long-term, alongside regular monitoring by your healthcare provider, such as Liver Function Tests (LFTs), kidney function testing, and HBV viral load testing.
LIVER BENEFITS
Vemlidy inhibits HBV DNA replication inside liver cells, targeting the source of the infection directly in the liver.
By blocking viral replication, Vemlidy helps reduce the amount of hepatitis B virus circulating in the bloodstream.
As viral load falls, the liver inflammation associated with chronic hepatitis B tends to decrease, which is a key goal of antiviral therapy.
Sustained viral suppression may help slow the progression of liver fibrosis and cirrhosis over the course of long-term treatment, though individual outcomes vary.
Vemlidy works directly on the hepatitis B virus in liver cells to reduce viral load and ease inflammation, with targeted delivery designed to lower kidney and bone exposure. It should only be started and monitored under the guidance of a qualified healthcare professional.
TREATMENT PROCESS
Vemlidy is supplied as an oral tablet. Take it exactly as prescribed by your healthcare provider, and check with your pharmacist if you have any questions about your specific tablet strength.
The typical dose is 25 mg once daily. Your healthcare provider determines the right dose for you.
Vemlidy is a once-daily oral tablet — it is not an injection or infusion. Take it with food, at the same time each day. Always use it exactly as your healthcare provider directs.
Vemlidy is generally used as a long-term or indefinite antiviral therapy for chronic hepatitis B. Treatment is continued as long as viral suppression is required and the medication is well tolerated, under ongoing medical supervision. Do not stop taking it without first talking to your healthcare provider.
Store Vemlidy tablets at room temperature, away from moisture and heat.
Your healthcare provider will regularly monitor liver function, kidney function, and HBV viral load. Report any side effects or unusual symptoms to your healthcare provider. Patients should also follow infection control precautions to reduce transmission risk.
BENEFITS AND SAFETY
Vemlidy (tenofovir alafenamide) may support people with chronic hepatitis B by acting directly in the liver to inhibit viral replication, reduce viral load, and ease the inflammation that drives disease progression. It is designed to deliver the active drug more efficiently to liver cells while lowering systemic exposure, giving it an improved kidney and bone safety profile compared with the older tenofovir formulation. The extent of these benefits varies from person to person, depending on liver condition, overall health, and how the body responds to therapy. Vemlidy is not a stand-alone treatment — it works best as part of a broader, personalized care plan that combines the medication with liver-healthy lifestyle habits and ongoing monitoring like Liver Function Tests (LFTs) and HBV viral load testing.
As with any medication, Vemlidy may cause side effects, ranging from mild symptoms such as headache and fatigue to elevated liver enzymes, which require monitoring. Your healthcare provider will monitor your liver and kidney function throughout treatment and assess whether Vemlidy remains a suitable option for you.
BENEFITS
Vemlidy reduces hepatitis B viral levels effectively by inhibiting HBV DNA replication in liver cells, helping achieve durable viral suppression.
Vemlidy's targeted delivery to hepatocytes means lower systemic exposure, giving it a lower impact on kidneys and bones compared with the older tenofovir disoproxil fumarate formulation.
By reducing viral load, Vemlidy helps decrease liver inflammation and liver damage associated with chronic hepatitis B.
Vemlidy is a once-daily oral tablet, offering a simple treatment routine without injections or infusions.
These effects are often more noticeable when starting treatment and may improve over time. Your healthcare provider will discuss the potential benefits and risks before treatment and provide ongoing support, including liver enzyme and kidney function monitoring, to ensure safe use.
SUPPORTING YOUR RESULTS
Vemlidy works best when combined with liver-healthy lifestyle habits. These habits, along with regular medical monitoring, help minimize other factors that may contribute to liver injury.
These habits can support how your liver responds to treatment and may help maximize the benefits of viral suppression over time.
Areas that may support treatment:
COMMON QUESTIONS
Vemlidy (tenofovir alafenamide) is taken as one 25 mg tablet by mouth once daily, with food, at the same time each day. Take it exactly as your healthcare provider prescribes, and do not change your dose without medical guidance. Store the tablets at room temperature, away from moisture and heat. Because Vemlidy is generally used long-term for chronic hepatitis B, consistency matters — missing doses can allow the virus to become active again. Talk with your healthcare provider about the best routine for remembering your daily dose.
Vemlidy may be appropriate for adults and certain pediatric patients with chronic hepatitis B who need long-term antiviral therapy, durable viral suppression, or a treatment option with an improved kidney and bone safety profile. Candidates often have elevated HBV DNA and ALT levels, or evidence of liver inflammation or fibrosis on testing. It is generally considered one of the preferred first-line oral therapies for chronic hepatitis B. Because eligibility depends on your viral load, liver health, kidney function, and other medications, a healthcare professional should evaluate your individual case before starting treatment.
No, Vemlidy is not a cure for hepatitis B. It is an antiviral medication that inhibits HBV DNA replication in liver cells, reducing viral load and easing the liver inflammation that drives disease progression. With sustained use, it may also help slow fibrosis and cirrhosis. However, hepatitis B typically requires long-term or indefinite treatment to keep the virus suppressed, since stopping therapy can allow it to become active again. Talk with your healthcare provider about realistic expectations and goals for your specific treatment plan.
Vemlidy (tenofovir alafenamide) and Viread (tenofovir disoproxil fumarate) both treat chronic hepatitis B by inhibiting HBV DNA replication, but they differ in formulation. Vemlidy delivers the active drug more efficiently to liver cells while reducing the amount that circulates elsewhere in the body, giving it an improved kidney and bone safety profile compared with Viread. Both are considered preferred first-line oral options for chronic hepatitis B. Your healthcare provider can help determine which formulation best fits your kidney function, bone health, and overall treatment goals.
Common side effects of Vemlidy include headache, fatigue, nausea, and abdominal discomfort. Some people also develop elevated liver enzymes, which require ongoing monitoring by a healthcare provider. These effects are often more noticeable when starting treatment and may improve over time. Vemlidy's targeted delivery to liver cells is designed to reduce systemic exposure, giving it a generally favorable kidney and bone safety profile compared with older tenofovir formulations. Report any new or worsening symptoms to your healthcare provider, who can adjust monitoring or treatment as needed.
Vemlidy is generally used as a long-term or indefinite antiviral therapy for chronic hepatitis B. Treatment continues as long as viral suppression is needed and the medication is well tolerated, under ongoing medical supervision. Because hepatitis B can become active again if treatment stops, do not discontinue Vemlidy without first talking to your healthcare provider. Your provider will periodically reassess your viral load, liver function, and overall health to confirm that continuing treatment remains the right choice for you.
While taking Vemlidy, your healthcare provider will regularly monitor your liver function, kidney function, and HBV viral load to confirm the medication is working and to catch side effects, such as elevated liver enzymes, early. Monitoring frequency depends on your individual health status and treatment history. Consistent follow-up testing helps ensure Vemlidy continues to suppress the virus safely over the long term. Always report new symptoms or concerns to your healthcare provider between scheduled visits.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
